IRIS
GIORDANO, GUIDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.620
NA - Nord America 1.604
AS - Asia 1.373
SA - Sud America 308
AF - Africa 27
OC - Oceania 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.935
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.546
SG - Singapore 593
IE - Irlanda 416
RU - Federazione Russa 402
CN - Cina 289
BR - Brasile 244
HK - Hong Kong 226
IT - Italia 184
SE - Svezia 174
DE - Germania 128
FR - Francia 116
VN - Vietnam 97
GB - Regno Unito 44
UA - Ucraina 39
FI - Finlandia 32
BD - Bangladesh 29
IN - India 26
MX - Messico 26
AE - Emirati Arabi Uniti 23
AR - Argentina 21
CA - Canada 19
NL - Olanda 18
PL - Polonia 18
ZA - Sudafrica 14
IQ - Iraq 13
VE - Venezuela 12
CZ - Repubblica Ceca 11
TR - Turchia 11
ID - Indonesia 10
AT - Austria 9
JP - Giappone 9
ES - Italia 8
JO - Giordania 8
EC - Ecuador 7
CO - Colombia 6
PY - Paraguay 6
CL - Cile 5
PK - Pakistan 5
SA - Arabia Saudita 5
AZ - Azerbaigian 4
LT - Lituania 4
UZ - Uzbekistan 4
ET - Etiopia 3
KZ - Kazakistan 3
NO - Norvegia 3
NP - Nepal 3
OM - Oman 3
RO - Romania 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
BE - Belgio 2
CG - Congo 2
DZ - Algeria 2
GY - Guiana 2
PH - Filippine 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
BO - Bolivia 1
BW - Botswana 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
IL - Israele 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
ME - Montenegro 1
MY - Malesia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.935
Salva come PNG Salva come JPEG
Città #
San Jose 479
Dublin 415
Singapore 284
Ashburn 227
Hong Kong 226
Dallas 154
Nyköping 134
Beijing 123
Santa Clara 93
Lauterbourg 77
Munich 54
New York 50
Moscow 43
Ho Chi Minh City 42
The Dalles 36
Princeton 35
Chandler 34
São Paulo 33
Jacksonville 27
Frankfurt am Main 25
Hanoi 23
Helsinki 21
Los Angeles 18
Seattle 18
Wilmington 16
Milan 15
Rome 14
Mexico City 13
Brooklyn 12
Chennai 11
Warsaw 11
Bari 10
Düsseldorf 10
Rio de Janeiro 10
Brno 9
London 9
Turku 9
Grosseto 8
Nuremberg 8
Shanghai 8
Amsterdam 7
Johannesburg 7
Orem 7
San Francisco 7
Tokyo 7
Amman 6
Boston 6
Dhaka 6
Falkenstein 6
Manchester 6
Montreal 6
Washington 6
Andria 5
Belo Horizonte 5
Chicago 5
Des Moines 5
Guangzhou 5
Stockholm 5
Assago 4
Atlanta 4
Baghdad 4
Bologna 4
Borås 4
Brasília 4
Chengdu 4
Haiphong 4
Martina Franca 4
Noicattaro 4
Phoenix 4
Porto Alegre 4
Potenza 4
Pune 4
São José do Rio Preto 4
Tashkent 4
Toronto 4
Viamão 4
Addis Ababa 3
Ankara 3
Biên Hòa 3
Cape Town 3
Changsha 3
Council Bluffs 3
Curitiba 3
Foggia 3
Izmir 3
Jakarta 3
Las Vegas 3
Manaus 3
Maringá 3
Marostica 3
Miami 3
Modugno 3
Ottawa 3
Paris 3
Pescara 3
Portsmouth 3
Riyadh 3
Roubaix 3
San Mateo 3
Schiffdorf 3
Totale 3.095
Salva come PNG Salva come JPEG
Nome #
Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports 113
Obstructive Sleep Apnea Worsens Progression-Free and Overall Survival in Human Metastatic Colorectal Carcinoma 102
Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines 99
Centrosome linker–induced tetraploid segregation errors link rhabdoid phenotypes and lethal colorectal cancers 96
Evidence‐based second‐line treatment in ras wild‐type/mutated metastatic colorectal cancer in the precision medicine era 91
CROC-Mutated rhabdoid colorectal carcinoma showing in intracellular spaces lamellipodia and cellular projectionts revealed by electron microscopy 90
Complete response to capecitabine in a frail, elderly patient with metastatic colorectal cancer: A case report 90
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice 89
Aberrant BLM cytoplasmic expressionassociates with DNA damage stress and hypersensitivity to DNA-damaging agents in colorectal cancer 89
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 88
Immune escape mechanisms in colorectal cancer pathogenesis and liver metastasis 88
Circulating Tumor DNA: A New Research Frontier in Urological Oncology from Localized to Metastatic Disease 87
Crosstalk between the tumor microenvironment and immune system in pancreatic ductal adenocarcinoma: Potential targets for new therapeutic approaches 87
Cancer drug related cardiotoxicity during breast cancer treatment 85
Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer 84
Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer 84
TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation 79
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 78
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 78
Colonic Ewing Sarcoma/PNET associated with liver metastases: A systematic review and case report 75
Morphology and molecular features of rare colorectal carcinoma histotypes 75
Androgen receptor, PARP signaling, and tumor microenvironment: the ‘perfect triad’ in prostate cancer? 74
Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. 73
Urothelial bladder carcinoma metastasizing to the eye: A systematic review and case report 73
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables 73
Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial 72
Bcl-10, trypsin and synaptophysin helps recognize acinar cell and mixed acinar neuroendocrine cell carcinoma of the pancreas on both preoperative cytological samples and needle biopsy specimens 72
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): A randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX 70
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 70
Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept 69
Emerging insight into MAPK inhibitors and immunotherapy in colorectal cancer 69
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) 69
Eribulin for metastatic breast cancer (MBC) treatment: A retrospective, multicenter study based in Campania, south Italy (Eri-001 trial) 68
Altered centriolar cohesion by CEP250 and appendages impact outcome of patients with pancreatic cancer 67
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 66
Solitary metastasis from renal cell carcinoma to the choroid plexus: A case illustration and review of the literature 66
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 64
Eribulin in male patients with breast cancer: The first report of clinical outcomes 63
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 63
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 63
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care 62
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 62
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 1: Focus on immunohistochemical results with discussion of pre-analytical and interpretation variables 61
Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process 57
The classification of neuroendocrine neoplasms of the lung and digestive system according to WHO, 5th edition: similarities, differences, challenges, and unmet needs 57
Metastatic melanoma: An unusual presentation 56
TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells 55
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1 55
Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era 54
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment 53
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes 53
Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives 50
Solitary fibrous tumor/hemangiopericytoma of the cervical spine: A systematic review of the literature with an illustrative case 50
Wnt (canonical and non canonical) pathways in breast carcinoma with extensive vascular invasion and inflammatory breast carcinoma 50
Single-cell proteo-genomic reveals a comprehensive map of centrosome-associated spliceosome components 50
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma 50
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 5: Epigenetic regulation of pd-l1 50
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 50
MiRNA expression affects survival in patients with obstructive sleep apnea and metastatic colorectal cancer 49
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions 49
Immune resistance and egfr antagonists in colorectal cancer 49
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment 49
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models) 49
Third whole-brain radiation therapy for multiple brain metastases. Should it be considered in selected patients? 48
What do we have to know about pd-l1 expression in prostate cancer? A systematic literature review. part 2: Clinic–pathologic correlations 46
What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. part 4: Experimental treatments in pre-clinical studies (cell lines and mouse models) 46
What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations 46
Multidisciplinary management of HER2-positive breast cancer with brain metastases: An evidence-based pragmatic approach moving from pathophysiology to clinical data 44
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review 44
Loss of Primary Cilia Potentiates BRAF/MAPK Pathway Activation in Rhabdoid Colorectal Carcinoma: A Series of 21 Cases Showing Ciliary Rootlet CoiledCoil (CROCC) Alterations 42
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 42
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life 41
Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer 40
Molecular and Clinical Insights in Malignant Brenner Tumor of the Testis With Liver Metastases:A Case Report 39
MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer 39
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 39
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 38
Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab‐paclitaxel plus gemcitabine as second or later‐line treatment 38
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data 37
Propensity for Early Metastatic Spread in Breast Cancer: Role of Tumor Vascularization Features and Tumor Immune Infiltrate 36
Evaluating CDK4/6 Inhibitor Therapy in Elderly Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: A Retrospective Real-World Multicenter Study 34
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) 33
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index 29
CDK4/6 Inhibitors in Patients Aged 80 and Older with HR+/HER2− Metastatic Breast Cancer: A Real-World Multicenter Study 28
Real-life second-line therapies outcome in metastatic pancreatic cancer (mPDAC) patients previously treated with gemcitabine plus nab-paclitaxel (Gem-Nab): An Italian multicenter study 18
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population 15
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study 10
Real-world Predictors of Early Mortality and Treatment Discontinuation in HCC Patients Treated with Atezolizumab–Bevacizumab 7
Totale 5.250
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.246
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.246
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202134 0 0 0 0 0 0 0 0 0 33 0 1
2021/2022150 3 0 1 1 10 2 11 15 21 39 2 45
2022/2023803 80 23 47 7 35 53 7 46 433 8 48 16
2023/2024275 27 23 25 19 24 77 13 22 5 3 2 35
2024/20251.360 47 23 33 105 43 272 94 116 229 116 136 146
2025/20262.501 161 339 248 292 145 122 500 295 267 132 0 0
Totale 5.250